These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23665445)

  • 1. Identification of aggregation breakers for bevacizumab (Avastin®) self-association through similarity searching and interaction studies.
    Westermaier Y; Veurink M; Riis-Johannessen T; Guinchard S; Gurny R; Scapozza L
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):773-80. PubMed ID: 23665445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation.
    Veurink M; Westermaier Y; Gurny R; Scapozza L
    Pharm Res; 2013 Apr; 30(4):1176-87. PubMed ID: 23412914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment.
    Veurink M; Stella C; Tabatabay C; Pournaras CJ; Gurny R
    Eur J Pharm Biopharm; 2011 Jun; 78(2):271-7. PubMed ID: 21172437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between reversible (self-association) and irreversible aggregation of rHuG-CSF in carbohydrate and polyol formulations.
    Pavišić R; Dodig I; Horvatić A; Mijić L; Sedić M; Linarić MR; Sovulj IG; Preočanin T; Krajačić MB; Cindrić M
    Eur J Pharm Biopharm; 2010 Nov; 76(3):357-65. PubMed ID: 20854908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association.
    Sudrik CM; Cloutier T; Mody N; Sathish HA; Trout BL
    Pharm Res; 2019 May; 36(8):109. PubMed ID: 31127417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.
    Roberts CJ; Nesta DP; Kim N
    J Pharm Sci; 2013 Oct; 102(10):3556-66. PubMed ID: 23873602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives.
    Wu G; Wang S; Tian Z; Zhang N; Sheng H; Dai W; Qian F
    Eur J Pharm Biopharm; 2017 Nov; 120():1-8. PubMed ID: 28754261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
    Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration.
    Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A
    Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Protein-Excipient Interaction Hotspots Using Computational Approaches.
    Barata TS; Zhang C; Dalby PA; Brocchini S; Zloh M
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27258262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDX and In Silico Docking Reveal that Excipients Stabilize G-CSF via a Combination of Preferential Exclusion and Specific Hotspot Interactions.
    Wood VE; Groves K; Cryar A; Quaglia M; Matejtschuk P; Dalby PA
    Mol Pharm; 2020 Dec; 17(12):4637-4651. PubMed ID: 33112626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanically-induced aggregation of the monoclonal antibody cetuximab.
    Lahlou A; Blanchet B; Carvalho M; Paul M; Astier A
    Ann Pharm Fr; 2009 Sep; 67(5):340-52. PubMed ID: 19695370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab).
    Peters BJ; Capelle MA; Arvinte T; van de Garde EM
    MAbs; 2013; 5(1):162-70. PubMed ID: 23255057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.
    Andya JD; Hsu CC; Shire SJ
    AAPS PharmSci; 2003; 5(2):E10. PubMed ID: 12866937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation.
    Kolhe P; Amend E; Singh SK
    Biotechnol Prog; 2010; 26(3):727-33. PubMed ID: 20039442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of polyol sugars on the stabilization of monoclonal antibodies.
    Nicoud L; Cohrs N; Arosio P; Norrant E; Morbidelli M
    Biophys Chem; 2015 Feb; 197():40-6. PubMed ID: 25645712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.
    Bowen M; Armstrong N; Maa YF
    J Pharm Sci; 2012 Dec; 101(12):4433-43. PubMed ID: 23001898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
    Fei M; Zhang Q; Zhang L; Zhu X; Du C; Zhang Z
    J Pharm Biomed Anal; 2023 Jan; 223():115121. PubMed ID: 36308924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.